All In Biotech

Drug Trial Radar · NCT06411379

Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 418 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

418

Actual

Start

May 14, 2024

Primary completion

Aug 14, 2025

Study completion May 20, 2026

Sponsor

Lead sponsor
MoonLake Immunotherapeutics AGIndustry
Sponsor type
Industry
First posted
May 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, care provider)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the clinical efficacy and safety of sonelokimab administered subcutaneously compared with placebo in the treatment of adult participants with moderate to severe hidradenitis suppurativa. Participants will be randomized 2:1 to either sonelokimab or matching placebo up to Week 16.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • SonelokimabDrug

    Sonelokimab

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hidradenitis Suppurativa Clinical Response 75Time frame: Week 16

Locations

106 sites in 12 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Birmingham, Alabama

  • Clinical Site

    North Little Rock, Arkansas

  • Clinical Site

    Fountain Valley, California

  • Clinical Site

    Santa Monica, California

  • Clinical Site

    Aventura, Florida

  • Clinical Site

    Hialeah, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Ocala, Florida

  • Clinical Site

    Tampa, Florida

  • Clinical Site

    Skokie, Illinois

  • Clinical Site

    Plainfield, Indiana

  • Clinical Site

    Murray, Kentucky

  • Clinical Site

    Baton Rouge, Louisiana

  • Clinical Site

    Baltimore, Maryland

  • Clinical Site

    Ann Arbor, Michigan

  • Clinical Site

    Canton, Michigan

  • Clinical Site

    Clarkston, Michigan

  • Clinical Site

    Waterford, Michigan

  • Clinical Site

    New Brighton, Minnesota

  • Clinical Site

    Omaha, Nebraska

  • Clinical Site

    Las Vegas, Nevada

  • Clinical Site

    New York, New York

  • Clinical Site

    Fargo, North Dakota

  • Clinical Site

    Columbus, Ohio

  • Clinical Site

    Murfreesboro, Tennessee

  • Clinical Site

    Dallas, Texas

  • Clinical Site

    Plano, Texas

  • Clinical Site

    San Antonio, Texas

  • Clinical Site

    Morgantown, West Virginia

  • Clinical Site

    Milwaukee, Wisconsin

  • Clinical Site

    Ghent, Belgium

  • Clinical Site

    Leuven, Belgium

  • Clinical Site

    Liège, Belgium

  • Clinical Site

    Woluwe-Saint-Lambert, Belgium

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Sofia, Bulgaria

  • Clinical Site

    Stara Zagora, Bulgaria

  • Clinical Site

    Calgary, Alberta, Canada

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.